Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16674
UPID:
MIA_HUMAN
Alternative names:
Melanoma inhibitory activity protein
Alternative UPACC:
Q16674; Q6FHV3
Background:
The Melanoma-derived growth regulatory protein, also known as Melanoma inhibitory activity protein, plays a crucial role in controlling the growth of melanoma cells and other neuroectodermal tumors such as gliomas. This protein's unique function highlights its importance in the regulation of tumor growth and development.
Therapeutic significance:
Understanding the role of Melanoma-derived growth regulatory protein could open doors to potential therapeutic strategies. Its ability to inhibit the growth of melanoma cells in vitro suggests a promising avenue for developing targeted treatments for melanoma and similar neuroectodermal tumors.